Registration Number
0214U002627,
0111U000377
, R & D reports
Title
Developing of the maintenance therapy in breast cancer patients who receive chemotherapy, considering clinical and laboratory of toxicity prognosis factors
popup.stage_title
Head
Syvak Liubov,
Registration Date
22-01-2014
Organization
Ukrainian Research Institute of Oncology and Radiology
popup.description2
The object of study - 146 patients with malignant breast tumors with toxic effects of chemotherapy in standard regimens. Purpose - to improve the results of chemotherapy and quality of life in patients with malignant breast tumors by developing maintenance therapy based on the clinical and laboratory prediction factors of toxicity of anticancer drugs. Methods and apparatus: clinical, laboratory, instrumental, statistical, ultrasound machine "Aloca", hematology analyzer BC-3000 biochemical analyzer "Vitros", spectrophotometer "Thermo", centrifuge "Biofuge", Thermostat "Termyt." As a result of clinical, laboratory, instrumental research and analysis of molecular genetic parameters during chemotherapy in patients with malignant breast tumors found that the standard regimens has a moderate (II-III) toxicity rate, the main manifestations of which are gastrointestinal (95.4%), cardiovascular (16.1%) and hematological (1.6%) toxicity. The most important prognostic factors for chemotherapy toxicity in patients with malignant breast tumors include age, concomitant diseases, especially cardiovascular system and gastrointestinal tract, cancerstage, previous anticancer treatment and the presence of the mutant allele G gene GSTP1 and T allele of the gene MTHFR. The risk of gastrointestinal toxicity was tenfold higher in patients with breast cancer with G/G phenotype of GSTP1 gene. The risk of cardiovascular complications was in 2.68 fold higher in patients with breast cancer with C/T or T/T genotype of MTHFR gene. The risk of hematological toxicity grade III was 10.75 fold higher in patients with breast cancer withC/T genotype of MTHFR gene. The main complications of chemotherapy in the group of patients with breast cancer with high risk of toxicity were gastrointestinal (80.5%), hepatic (75.0%) cardiovascular (94.4%) and hematological (47.2%) toxicity. The usage of developed algorithms of supportive care of standard chemotherapy regimens in patients with breast cancer with high risk of toxicity allowed to conduct treatment in full amount without decrease of doses of cytostatics and in planned terms. It also allowed to decrease the level of emetic syndrome as the manifestation of gastrointestinal toxicity on 30%, early hepatic toxicity on 8.2% and early cardiovascular toxicity on 25.1%. These improved the results of treatment and quality of life of patients. The overall response rate was higher on 18.3% without decrease of quality of life of patients. Field of implementation: oncology.
Product Description
popup.authors
Алексик Олена Олексіївна
Аскольський Антон Вячеславович
Губарева Ганна Олександрівна
Кліманов Михайло Юрійович
Лялькін Сергій Анатолійович
Майданевич Наталя Миколаївна
Свергун Наталя Миколаївна
Сивак Любов Андріївна
Філоненко Катерина Сергіївна
Шевчук Леся Анатоліївна
popup.nrat_date
2020-04-02
